SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012234
Filing Date
2024-08-14
Accepted
2024-08-14 16:15:28
Documents
71
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20240630x10q.htm   iXBRL 10-Q 1611465
2 EX-10.1 otlk-20240630xex10d1.htm EX-10.1 192271
3 EX-10.2 otlk-20240630xex10d2.htm EX-10.2 116527
4 EX-31.1 otlk-20240630xex31d1.htm EX-31.1 9605
5 EX-31.2 otlk-20240630xex31d2.htm EX-31.2 12101
6 EX-32.1 otlk-20240630xex32d1.htm EX-32.1 9504
  Complete submission text file 0001558370-24-012234.txt   8092655

Data Files

Seq Description Document Type Size
7 EX-101.SCH otlk-20240630.xsd EX-101.SCH 45921
8 EX-101.CAL otlk-20240630_cal.xml EX-101.CAL 48337
9 EX-101.DEF otlk-20240630_def.xml EX-101.DEF 209631
10 EX-101.LAB otlk-20240630_lab.xml EX-101.LAB 400452
11 EX-101.PRE otlk-20240630_pre.xml EX-101.PRE 350306
74 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20240630x10q_htm.xml XML 1498840
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 241208034
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)